Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.

Details

Ressource 1Download: 36619367_BIB_5989E895E6D7.pdf (6021.78 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_5989E895E6D7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.
Journal
iScience
Author(s)
Emmenegger M., De Cecco E., Lamparter D., Jacquat RPB, Riou J., Menges D., Ballouz T., Ebner D., Schneider M.M., Morales I.C., Doğançay B., Guo J., Wiedmer A., Domange J., Imeri M., Moos R., Zografou C., Batkitar L., Madrigal L., Schneider D., Trevisan C., Gonzalez-Guerra A., Carrella A., Dubach I.L., Xu C.K., Meisl G., Kosmoliaptsis V., Malinauskas T., Burgess-Brown N., Owens R., Hatch S., Mongkolsapaya J., Screaton G.R., Schubert K., Huck J.D., Liu F., Pojer F., Lau K., Hacker D., Probst-Müller E., Cervia C., Nilsson J., Boyman O., Saleh L., Spanaus K., von Eckardstein A., Schaer D.J., Ban N., Tsai C.J., Marino J., Schertler GFX, Ebert N., Thiel V., Gottschalk J., Frey B.M., Reimann R.R., Hornemann S., Ring A.M., Knowles TPJ, Puhan M.A., Althaus C.L., Xenarios I., Stuart D.I., Aguzzi A.
ISSN
2589-0042 (Electronic)
ISSN-L
2589-0042
Publication state
Published
Issued date
17/02/2023
Peer-reviewed
Oui
Volume
26
Number
2
Pages
105928
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72'250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.
Keywords
Biological database, Immunology, Microbiology, Virology
Pubmed
Web of science
Open Access
Yes
Create date
16/01/2023 11:14
Last modification date
23/01/2024 7:26
Usage data